Banner
  • Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Exelixis ASCO Abstracts Might Not Ease Setback from 2011

Article

After a disappointing end to 2011 regarding its lead drug, Exelixis is looking to bounce back with new data in its ASCO abstracts.

After a disappointing end to 2011 regarding its lead drug, Exelixis (EXEL) is looking to bounce back with new data. The company filed an abstract with ASCO showing results from use of cabozantinib in medullary thyroid cancer patients and another abstract on the drug in a Phase II study for prostate cancer.

Exelixis will give nine presentations on cabozantinib at this year’s ASCO conference. In the medullary thyroid cancer study, the drug provided an additional 7.2 months of progression-free survival over a placebo and a 28% response rate.

The drug was also used in a Phase II study of 93 patients with advanced prostate cancer that had spread to bone. The abstract results revealed that 60% of patients had a partial bone scan response, while 70% had reduction of measurable disease, according to TheStreet.com.

Exelixis is struggling to bounce back from a tough end of 2011 when the company saw its stock price cut in half after a regulatory disappointment. In November, Exelixis couldn’t reach an agreement with the FDA regarding Phase III trial for cabozantinib in prostate cancer, according to SeekingAlpha.

Click to enlarge

The stock price is languishing at the lower end of its 52-week range, which runs from as low as $3.94 to as high as $11.74.

However, the new data might not be enough for Exelixis. Since the abstracts were released the company’s stock has been on a steady decline. While it started the week over $5, it is now down to $4.62.

The information contained in this article should not be construed as investment advice or as a solicitation to buy or sell any stock.

Read more:

ASCO ’12 Abstract Dump: Cancer Stocks in FocusExelixis: Setting the Facts Straight

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice